Inhibition of aldehyde dehydrogenase by furazolidone nanoemulsion to decrease cisplatin resistance in lung cancer cells

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung cancer. In: Seminars in Interventional Radiology. Thieme Medical Publishers, NY, USA, 93–98 (2013).
  Google Scholar
• 2. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J. Clin. 62(1), 10–29 (2012).
  MedlineGoogle Scholar
• 3. Miller KD, Siegel RL, Lin CC et al. Cancer treatment and survivorship statistics. CA Cancer J. Clin. 66(4), 271–289 (2016).
  MedlineGoogle Scholar
• 4. Tiseo M, Ardizzoni A. Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review. Oncol Rev. 1(3), 162–169 (2007).
  Google Scholar
• 5. Kim ES. Chemotherapy resistance in lung cancer. In: Lung Cancer and Personalized Medicine. Springer, Switzerland, 189–209 (2016). • The role of aldehyde dehydrogenase in human cancer stem cells.
  Google Scholar
• 6. Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. Rep. 7(2), 292–306 (2011).
  Medline CASGoogle Scholar
• 7. Khoury T, Ademuyiwa FO, Chandraseekhar R et al. Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Mod. Pathol. 25(3), 388–297 (2012).
  Medline CASGoogle Scholar
• 8. Alamgeer M, Ganju V, Szczepny A et al. The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. Thorax 7, 292–306 (2013).
  Google Scholar
• 9. Wei Y, Wu S, Xu W et al. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP. Thorac. Cancer. 8(1), 26–32 (2017).
  Medline CASGoogle Scholar
• 10. Koppaka V, Thompson DC, Chen Y et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol. Rev. 64(3), 520–539 (2016). • The role of aldehyde dehydrogenase inhibition in reducing the chemotherapy resistance of stem-like.
  Google Scholar
• 11. Croker AK, Allan AL. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDH hi CD44+ human breast cancer cells. Breast Cancer Res. Treat. 133(1), 75–87 (2012).
  Medline CASGoogle Scholar
• 12. Petri WA. Treatment of giardiasis. Curr. Treat Options Gastroenterol. 8(1), 13–17 (2005).
  MedlineGoogle Scholar
• 13. Deng S, Tang S, Dai C et al. P21Waf1/Cip1 plays a critical role in furazolidone-induced apoptosis in HepG2 cells through influencing the caspase-3 activation and ROS generation. Food Chem. Toxicol. 88, 1–2 (2016).
  Medline CASGoogle Scholar
• 14. Jin X, Tang S, Chen Q et al. Furazolidone induced oxidative DNA damage via up-regulating ROS that caused cell cycle arrest in human hepatoma G2 cells. Toxicol. Lett. 201(3), 205–212 (2011). • Anticancer effect of furazolidone.
  Medline CASGoogle Scholar
• 15. Jiang X, Sun L, Qiu JJ et al. A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia. PloS ONE 8(8), e72335 (2013).
  Medline CASGoogle Scholar
• 16. Karamanakos PN, Pappas P, Boumba VA et al. Pharmaceutical agents known to produce disulfiram-like reaction: effects on hepatic ethanol metabolism and brain monoamines. Int. J. Toxicol. 26(5), 423–432 (2007).
  Medline CASGoogle Scholar
• 17. Karamanakos PN. Possible role for furazolidone in the treatment of glioblastoma multiforme. J. Buon. 18(4), 1097 (2013).
  MedlineGoogle Scholar
• 18. Kast RE, Belda-Iniesta C. Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: a hypothesis. Curr. Stem Cell Res. Ther. 4(4), 314–317 (2009).
  Medline CASGoogle Scholar
• 19. Tempone AG, Mortara RA, De Andrade HF, Reimão JQ. Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis. Int. J. Antimicrob. Agents. 36(2), 159–163 (2010). •• Formulation of furazolidone in liposomes.
  Medline CASGoogle Scholar
• 20. Alam MI, Paget T, Elkordy AA. Formulation and advantages of furazolidone in liposomal drug delivery systems. Eur. J. Pharm.Sci. 84, 139–145 (2016).
  Medline CASGoogle Scholar
• 21. Praveen Kumar G, Divya A. Nanoemulsion based targeting in cancer therapeutics. Med. Chem. 5, 272–284 (2015).
  Google Scholar
• 22. Souto EB, Nayak AP, Murthy RS. Lipid nanoemulsions for anti-cancer drug therapy. Pharmazie. 66(7), 473–478 (2011).
  Medline CASGoogle Scholar
• 23. Tiwari SB, Nanoemulsion formulations for tumor-targeted delivery. In: Nanotechnology for cancer therapy. Amiji MM (Ed.). Taylor and Francis Group, NY, USA, 723–739 (2006).
  Google Scholar
• 24. Moreb JS, Zucali JR, Ostmark B, Benson NA. Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by Aldefluor flow cytometry‐based assay. Cytometry B. Clin. Cytom. 72(4), 281–289 (2007).
  MedlineGoogle Scholar
• 25. Moghimipour E, Salimi A, Eftekhari S. Design and characterization of microemulsion systems for naproxen. Adv. Pharm. Bull. 3(1), 63–71 (2013).
  MedlineGoogle Scholar
• 26. Bostian KA, Betts GF. Rapid purification and properties of potassium-activated aldehyde dehydrogenase from Saccharomyces cerevisiae. Bioch. J. 173(3), 773–786 (1978).
  Medline CASGoogle Scholar
• 27. Moreb JS, Ucar D, Han S et al. The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem. Biol. Interact. 195(1), 52–60 (2012).
  Medline CASGoogle Scholar
• 28. Pham-The H, Garrigues T, Bermejo M, González-Álvarez I, Monteagudo MC, Cabrera-Pérez MA. Provisional classification and in silico study of biopharmaceutical system based on Caco-2 cell permeability and dose number. Mol. Pharm. 10(6), 2445–2461 (2013). •• Formulation of nanoemulsions.
  Medline CASGoogle Scholar
• 29. Gao Y, Qi X, Zheng Y et al. Nanoemulsion enhances α-tocopherol succinate bioavailability in rats. Int. J. Pharm. 515(1-2), 506–514 (2016).
  Medline CASGoogle Scholar
• 30. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur. J. Pharm. Biopharm. 66(2), 227–243 (2007).
  Medline CASGoogle Scholar
• 31. Ma WC, Zhang Q, Li H et al. Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy. Int. J. Pharm. 450(1-2), 21–30 (2013).
  Medline CASGoogle Scholar
• 32. Đorɖević SM, Radulović TS, Cekić ND et al. Experimental design in formulation of diazepam nanoemulsions: physicochemical and pharmacokinetic performances. J. Pharm. Sci. 102(11), 4159–4172 (2013).
  Medline CASGoogle Scholar
• 33. Đorđević SM, Cekić ND, Savić MM et al. Parenteral nanoemulsions as promising carriers for brain delivery of risperidone: design, characterization and in vivo pharmacokinetic evaluation. Int. J. Pharm. 493(1-2), 40–54 (2015).
  MedlineGoogle Scholar
• 34. Moghimi SM, Hunter AC. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol. 18(10), 412–420 (2000).
  Medline CASGoogle Scholar
• 35. Moghimi SM, Muir IS, Illum L, Davis SS, Kolb-Bachofen V. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim. Biophys. Acta 1179(2), 157–165 (1993).
  Medline CASGoogle Scholar
• 36. Illum L, West P, Washington C, Davis SS. The effect of stabilising agents on the organ distribution of lipid emulsions. Int. J. Pharm. 54(1), 41–49 (1989).
  CASGoogle Scholar
• 37. Kim JY, Choi WI, Kim YH et al. In-vivo tumor targeting of pluronic-based nano-carriers. J. Control. Rel. 147(1), 109–117 (2010).
  Medline CASGoogle Scholar
• 38. Li Y, Zheng J, Xiao H, McClements DJ. Nanoemulsion-based delivery systems for poorly water-soluble bioactive compounds: influence of formulation parameters on polymethoxyflavone crystallization. Food Hydrocoll. 27(2), 517–528 (2012).
  Medline CASGoogle Scholar
• 39. Gao K, Sun J, Liu K, Liu X, He Z. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev. Ind. Pharm. 34(11), 1227–1237 (2008).
  Medline CASGoogle Scholar
• 40. Araújo FA, Kelmann RG, Araujo BV, Finatto RB, Teixeira HF, Koester LS. Development and characterization of parenteral nanoemulsions containing thalidomide. Eur. J. Pharm. Sci. 42(3), 238–245 (2011).
  Medline CASGoogle Scholar
• 41. Mitri K, Shegokar R, Gohla S, Anselmi C, Müller RH. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance. Int. J. Pharm. 414(1–2), 267–275 (2011).
  Medline CASGoogle Scholar
• 42. Carbone C, Tomasello B, Ruozi B, Renis M, Puglisi G. Preparation and optimization of PIT solid lipid nanoparticles via statistical factorial design. Eur. J. Med. Chem. 49, 110–117 (2012).
  Medline CASGoogle Scholar
• 43. Zhou H, Yue Y, Liu G et al. Preparation and characterization of a lecithin nanoemulsion as a topical delivery system. Nanoscale Res. Lett. 5(1), 224–230 (2010).
  CASGoogle Scholar
• 44. Schuh RS, Bruxel F, Teixeira HF. Physicochemical properties of lecithin-based nanoemulsions obtained by spontaneous emulsification or high-pressure homogenization. Química Nova. 37(7), 1193–1198 (2014).
  CASGoogle Scholar
• 45. Redhead HM, Davis SS, Illum L. Drug delivery in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation.. J. Control. Rel. 70(3), 353–363 (2001).
  Medline CASGoogle Scholar
• 46. Kamel AO, Awad GA, Geneidi AS, Mortada ND. Preparation of intravenous stealthy acyclovir nanoparticles with increased mean residence time. AAPS Pharm. Sci. Tech. 10(4), 1427 (2009).
  Medline CASGoogle Scholar
• 47. Morsi N, Ibrahim M, Refai H, El Sorogy H. Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide. Eur. J. Pharm. Sci. 104, 302–314 (2017).
  Medline CASGoogle Scholar
• 48. Vass M, Hruska K, Franek M. Nitrofuran antibiotics: a review on the application, prohibition and residual analysis. Vet Med - Czech. 53(9), 469–500 (2008).
  CASGoogle Scholar
• 49. Ganta S, Talekar M, Singh A, Coleman TP, Amiji MM. Nanoemulsions in translational research – opportunities and challenges in targeted cancer therapy. Aaps Pharm. Sci. Tech. 15(3), 694–708 (2014).
  Medline CASGoogle Scholar
• 50. Akbari J, Saeedi M, Morteza-Semnani K et al. The design of naproxen solid lipid nanoparticles to target skin layers. Colloids Surf. B. 145, 626–633 (2016).
  Medline CASGoogle Scholar
• 51. Yu H, Pan L, Li P et al. Nitrofurantoin enteric pellets with high bioavailability based on aciform crystalline formation by wet milling. Pharm. Dev. Technol. 20(4), 433–441 (2015).
  Medline CASGoogle Scholar
• 52. Vangala VR, Chow PS, Tan RB. The solvates and salt of antibiotic agent, nitrofurantoin: structural, thermochemical and desolvation studies. Cryst. Eng. Comm. 15(5), 878–889 (2013).
  CASGoogle Scholar
• 53. Craig DQ, Reading M. Thermal Analysis of Pharmaceuticals. CRC Press, FL, USA (2006).
  Google Scholar
• 54. Singh S, Junwal M, Modhe G et al. Forced degradation studies to assess the stability of drugs and products. Trends Anal. Chem. 49, 71–88 (2013).
  CASGoogle Scholar
• 55. Abdou EM, Kandil SM, El Miniawy HM. Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion. Int. J. Pharm. 529(1-2), 667–677 (2017).
  Medline CASGoogle Scholar
• 56. Fraga M, Laux M, Rejane dos Santos G et al. Evaluation of the toxicity of oligonucleotide/cationic nanoemulsion complexes on Hep G2 cells through MTT assay. Pharmazie. 63(9), 667–670 (2008).
  Medline CASGoogle Scholar
• 57. Li Y, Le Maux S, Xiao H, McClements DJ. Emulsion-based delivery systems for tributyrin, a potential colon cancer preventative agent. J. Agric. Food Chem. 57(19), 9243–9249 (2009).
  Medline CASGoogle Scholar
• 58. Choudhury H, Gorain B, Karmakar S et al. Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform. Int. J. Pharm. 460(1-2), 131–143 (2014).
  Medline CASGoogle Scholar
• 59. Díaz C, Vargas E, Gätjens-Boniche O. Cytotoxic effect induced by retinoic acid loaded into galactosyl-sphingosine containing liposomes on human hepatoma cell lines. Int. J. Pharm. 325(1-2), 108–115 (2006).
  Medline CASGoogle Scholar
• 60. Jiang SP, He SN, Li YL et al. Preparation and characteristics of lipid nanoemulsion formulations loaded with doxorubicin. Int. J. Nanomed. 8, 3141–3150 (2013).
  MedlineGoogle Scholar
• 61. Galluzzi L, Senovilla L, Vitale I et al. Molecular mechanisms of cisplatin resistance. Oncogene 31(15), 1869–1883 (2012).
  Medline CASGoogle Scholar
• 62. Singh S, Brocker C, Koppaka V et al. Aldehyde dehydrogenases in cellular responses to oxidative/electrophilicstress. Free Radic. Biol. Med. 56, 89–101 (2013).
  Medline CASGoogle Scholar
• 63. Gross ER, Zambelli VO, Small BA, Ferreira JC, Chen CH, Mochly-Rosen D. A personalized medicine approach for Asian Americans with the aldehyde dehydrogenase 2* 2 variant. Annu. Rev. Pharmacol. Toxicol. 55, 107–127 (2015).
  Medline CASGoogle Scholar
• 64. Kim J, Chen CH, Yang J, Mochly-Rosen D. Aldehyde dehydrogenase 2* 2 knock-in mice show increased reactive oxygen species production in response to cisplatin treatment. J. Biomed. Sci. 24(1), 33 (2017).
  MedlineGoogle Scholar
• 65. Russo JE, Hilton J. Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells. Cancer Res. 48(11), 2963–2968 (1988).
  Medline CASGoogle Scholar
• 66. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm. Res. 23(12), 2709–272 (2006).
  Medline CASGoogle Scholar
• 67. Tanei T, Morimoto K, Shimazu K et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 15(12), 4234–4441 (2009).
  Medline CASGoogle Scholar
• 68. Moreb JS, Baker HV, Chang LJ et al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol. Cancer 7(1), 87 (2008).
  MedlineGoogle Scholar
• 69. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. PNAS 99(12), 8306–8611 (2002).
  Medline CASGoogle Scholar
• 70. Wenzel P, Hink U, Oelze M et al. Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity: implications for mitochondrial oxidative stress and nitrate tolerance. J. Biol. Chem. 282(1), 792–799 (2007).
  Medline CASGoogle Scholar
• 71. Zhou L, Ishizaki H, Spitzer M et al. ALDH2 mediates 5-nitrofuran activity in multiple species. Chem. Bio. 19(7), 883–892 (2012).
  Medline CASGoogle Scholar
• 72. Sarvi S, Crispin R, Lu Y et al. ALDH1 bio-activates nifuroxazide to eradicate ALDH high melanoma-initiating cells. Cell Chem Biol. 25(12), 1456–1469 (2018).
  Medline CASGoogle Scholar
• 73. Maya JD, Cassels BK, Iturriaga-Vásquez P et al. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 146(4), 601–620 (2007).
  MedlineGoogle Scholar
• 74. Yu JG, Ji CH, Shi MH. The anti‐infection drug furazolidone inhibits NF‐κB signaling and induces cell apoptosis in small cell lung cancer. Kaohsiung J. Med. Sci. 36(12), 998–1003 (2020).
  Medline CASGoogle Scholar
• 75. Deng S, Tang S, Zhang S et al. Furazolidone induces apoptosis through activating reactive oxygen species-dependent mitochondrial signaling pathway and suppressing PI3K/Akt signaling pathway in HepG2 cells. Food Chem. Toxicol. 75, 173–186 (2015).
  Medline CASGoogle Scholar